Below are your results for the search term: nhl or lymphoma

Search Again    Back to previous page

• 1. Jak kinase activity is required for lymphoma invasion and metastasis.
• 2. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
• 3. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
• 4. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
• 5. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
• 6. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
• 7. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
• 8. Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma.
• 9. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
• 10. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
• 11. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
• 12. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
• 13. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
• 14. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
• 15. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
• 16. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
• 17. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
• 18. Stimulation of CD95-induced apoptosis in T-cells by a subtype specific neutral sphingomyelinase inhibitor.
• 19. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors.
• 20. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
• 21. An international cohort study of cancer in systemic lupus erythematosus.
• 22. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.
• 23. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
• 24. Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.
• 25. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression.
• 26. Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.
• 27. Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy.
• 28. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
• 29. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.
• 30. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
• 31. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
• 32. Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.
• 33. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
• 34. A peptide aptamer to antagonize BCL-6 function.
• 35. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
• 36. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
• 37. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.
• 38. Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells.
• 39. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
• 40. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation.
• 41. Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
• 42. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
• 43. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
• 44. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
• 45. Proteomic profiling of mature CD10+ B-cell lymphomas.
• 46. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
• 47. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
• 48. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
• 49. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
• 50. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways.

1 - 50 results more>>